Prognostication of Follicular Lymphoma: A Review of Prognostic Scores and Factors
Diagnostics,
Journal Year:
2025,
Volume and Issue:
15(5), P. 647 - 647
Published: March 6, 2025
Follicular
lymphoma
(FL)
is
an
indolent,
rarely
curable
B-cell
malignancy
with
a
heterogeneous
clinical
course.
While
generally
treatable,
FL
characterized
by
remissions
and
relapses,
its
presentation
varies
widely.
Rituximab
has
revolutionized
treatment,
significantly
improving
overall
survival
over
the
past
two
decades.
Risk
assessment
typically
relies
on
histological
grade,
tumor
burden,
Lymphoma
International
Prognostic
Index,
which
incorporates
factors
like
age,
hemoglobin
level,
Ann
Arbor
stage.
However,
these
indices
have
limitations
in
fully
capturing
variability
of
FL.
Some
patients
experience
indolent
disease
for
extended
periods
without
requiring
while
others
present
aggressive
forms
resistant
to
standard
therapies.
This
review
examines
various
prognostic
FL,
including
FLIPI,
FLIPI2,
PRIMA-PI,
m7-FLIPI.
The
based
five
risk
factors,
stratifies
into
low-,
intermediate-,
high-risk
groups.
FLIPI2
beta2-microglobulin
longest
diameter
largest
involved
node,
offering
improved
prognostication.
designed
receiving
rituximab-containing
regimens,
uses
beta2-microglobulin,
bone
marrow
involvement,
node.
m7-FLIPI
integrates
mutational
status
parameters,
further
refining
stratification.
also
discusses
parameters
maximum
standardized
uptake
value
PET/CT
lymphocyte/monocyte
ratio
as
factors.
A
high
SUVmax
low
identify
patients.
remains
incurable,
advances
immunochemotherapy
targeted
therapies
outcomes.
provides
comprehensive
overview
tools
emphasizing
importance
stratification
personalized
treatment
strategies.
Language: Английский
Circulating tumor DNA in lymphoma: technologies and applications
Journal of Hematology & Oncology,
Journal Year:
2025,
Volume and Issue:
18(1)
Published: March 11, 2025
Lymphoma,
a
malignant
tumor
derived
from
lymphocytes
and
lymphoid
tissues,
presents
with
complex
heterogeneous
clinical
manifestations,
requiring
accurate
patient
classification
for
appropriate
treatment.
While
invasive
pathological
examination
of
lymph
nodes
or
tissue
remains
the
gold
standard
lymphoma
diagnosis,
its
utility
is
limited
in
cases
deep-seated
tumors
such
as
intraperitoneal
central
nervous
system
lymphomas.
In
addition,
biopsy
procedures
carry
an
inherent
risk
complications.
Computed
tomography
(CT)
positron
emission
tomography/computed
(PET/CT)
imaging
are
essential
treatment
assessment
monitoring,
but
lack
ability
to
detect
early
clonal
evolution
minimal
residual
disease
(MRD).
Liquid
biopsy-based
analysis
circulating
DNA
(ctDNA)
offers
non-invasive
alternative
that
allows
repeated
sampling
overcomes
limitations
spatial
heterogeneity
biopsies.
ctDNA
provides
genetic
epigenetic
insights
into
serves
dynamic,
quantifiable
biomarker
stratification,
response.
This
review
comprehensively
summarizes
common
variations
systematically
evaluates
detection
technologies,
including
PCR-based
assays
next-generation
sequencing
(NGS).
Applications
noninvasive
genotyping,
therapeutic
response
MRD
discussed
across
various
subtypes,
diffuse
large
B-cell
lymphoma,
Hodgkin
follicular
T-cell
lymphoma.
By
integrating
recent
research
findings,
highlights
role
profiling
advancing
precision
medicine,
enabling
personalized
strategies,
improving
outcomes
Language: Английский